Rani Therapeutics Holdings, Inc. Class A Common Stock
1.40
USD
Gesponsert
0.00
0.00%
09. Jan., 15:59 UTC -5
Geschlossen
Vor-Markt
1.43
+0.03
+2.14%
RANI Ergebnisberichte
Positives Überraschungsverhältnis
RANI übertreffen die 15 der letzten 18Schätzungen.
83%
Nächster Bericht
Datum des nächsten Berichts
--
Estimate forQ-- --(Revenue/ EPS)
--
/
--
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
--
Implizierte Änderung vonQ-- -1(Revenue/ EPS)
--
/
--
Rani Therapeutics Holdings, Inc. Class A Common Stock earnings per share and revenue
On 06. Nov. 2025, RANI reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 4.61% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -11.01% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Rani Therapeutics Holdings, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Rani Therapeutics Holdings, Inc. Class A Common Stock reported EPS of -$0.12, beating estimates by 4.61%, and revenue of $0.00, 0% as expectations.
How did the market react to Rani Therapeutics Holdings, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -11.01%, changed from $2.27 before the earnings release to $2.02 the day after.
When is Rani Therapeutics Holdings, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Rani Therapeutics Holdings, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Rani Therapeutics Holdings, Inc. Class A Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.